Literature DB >> 10758320

Neonatal neoplasms.

E C Halperin1.   

Abstract

PURPOSE: To describe neoplasms diagnosed in children </= 28 days of age along with their treatment, associated congenital anomalies, and the long-term consequences of the diagnoses and treatments. METHODS AND MATERIALS: Utilizing autopsy records, a computerized tumor registry, and medical records, we identified patients and stillborns at Duke University Medical Center (DUMC) diagnosed with neoplasms at </= 28 days of age between 1930 and 1998.
RESULTS: Twenty-three neonates with neoplasms were identified. There were 7 males (30%) and 16 females (70%). Follow-up of survivors ranged from 4 months to 27 years (mean 9 years). The 20 patients identified via the computerized registry system for 1980-1998 constitute 2% (20/925) of all neoplasms seen in patients </= 16 years of age over this same time period at DUMC. The histologic diagnoses were teratoma/germ cell tumor (n = 8, 35%), neuroblastoma (n = 5, 22%), retinoblastoma (n = 4, 17%), primary central nervous system (CNS) tumor (n = 3, 13%), and one case each of rhabdomyosarcoma, glossal glial choristoma, and hemangioma in the setting of Kasabach-Merritt Syndrome. Of the eight teratoma/germ cell tumor patients, 6 were female (75%) and 2 male (25%). There was one malignant germ cell tumor, 2 immature teratomas, and 5 teratomas. Two of the seven patients with immature teratomas or teratoma were long-term survivors following surgery. The one patient with malignant germ cell tumor, treated with surgery and chemotherapy, died. Associated anomalies were imperforate anus, congenital absence of a limb, left ventricular hypertrophy, fusion or absence of toes, coarctation of the aorta, and pulmonary valve dysplasia. Of the five children with neuroblastoma, 4 were female. INSS Stages were 1 (n = 1), 2A (n = 1), 3 (n = 1), and 4S (n = 2). Two were treated with surgery + chemotherapy + radiotherapy; two with surgery + chemotherapy; and one with surgery alone. Four children are long-term survivors. Associated congenital anomalies and medical problems were ventricular septal defect, seizure disorder, and Fanconi's anemia. A child with a dumbbell neuroblastoma, treated with surgery and chemotherapy, is paraplegic. Of the four children with retinoblastoma, two were female. Two had trilateral disease and two bilateral. Three of the four had a family history of retinoblastoma. The two children with trilateral retinoblastoma died after therapy with surgery, craniospinal and orbital irradiation, and chemotherapy. Two children with bilateral disease are long-term survivors: one treated with radiotherapy + chemotherapy and one with radiotherapy alone. They have marked orbital bone growth abnormalities. The three patients with CNS tumors were female. The histologies were glioblastoma multiforme, anaplastic astrocytoma, and malignant mixed oligodendroglioma. Two of the patients are long-term survivors after surgery + chemotherapy. Six children received eight courses of radiation therapy: 2 for Stage 4S neuroblastoma with respiratory compromise from an enlarging liver and 4 for retinoblastoma. The two infants with trilateral retinoblastoma received two courses of irradiation each: one of the treatment of intraocular tumor and a second, at an older age, for the pineal tumor. The most serious complication of anesthesia was a case of enterobacter cloacae sepsis in the central venous access line used for repetitively administering the anesthetic.
CONCLUSION: The most common neonatal neoplasm histologic diagnoses are teratoma/germ cell tumor, neuroblastoma, and retinoblastoma. Neonatal neoplasms may be associated with congenital anomalies. Radiation therapy is administered infrequently in a population highly susceptible to late ill effects. When radiotherapy is required, anesthesia may be repetitively administered to aid in reproducible treatment.

Entities:  

Mesh:

Year:  2000        PMID: 10758320     DOI: 10.1016/s0360-3016(00)00424-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

Review 1.  Neonatal tumours.

Authors:  S W Moore
Journal:  Pediatr Surg Int       Date:  2013-10-31       Impact factor: 1.827

2.  A report of nine newborns with congenital brain tumours.

Authors:  Henrik Carstensen; Marianne Juhler; Lars Bøgeskov; Henning Laursen
Journal:  Childs Nerv Syst       Date:  2006-06-28       Impact factor: 1.475

3.  Congenital gemistocytic astrocytoma in a fetus.

Authors:  Michimasa Nozaki; Akiko Ohnishi; Takamitsu Fujimaki; Kazuo Nagashima; Kazutoshi Cho; Yutaka Sawamura
Journal:  Childs Nerv Syst       Date:  2005-04-30       Impact factor: 1.475

4.  Trilateral retinoblastoma: A systematic review of 211 cases.

Authors:  Ryuya Yamanaka; Azusa Hayano; Yasuo Takashima
Journal:  Neurosurg Rev       Date:  2017-08-16       Impact factor: 3.042

5.  Clinical and molecular characteristics of congenital glioblastoma.

Authors:  Margaret E Macy; Diane K Birks; Valerie N Barton; Michael H Chan; Andrew M Donson; B K Kleinschmidt-Demasters; Lynne T Bemis; Michael H Handler; Nicholas K Foreman
Journal:  Neuro Oncol       Date:  2012-06-18       Impact factor: 12.300

6.  Differential diagnosis of leukocoria and strabismus, first presenting signs of retinoblastoma.

Authors:  Aubin Balmer; Francis Munier
Journal:  Clin Ophthalmol       Date:  2007-12

7.  Neonatal tumours in Malaysia: a call for heightened awareness.

Authors:  Badrul Hisham Yeap; Zakaria Zahari
Journal:  Pediatr Surg Int       Date:  2009-11-11       Impact factor: 1.827

8.  Glial choristoma.

Authors:  P Bajaj; B S Shubha; K Agarwal; C Aggarwal
Journal:  Indian J Pediatr       Date:  2002-05       Impact factor: 1.967

Review 9.  The epidemiology of neonatal tumours. Report of an international working group.

Authors:  S W Moore; D Satgé; A J Sasco; A Zimmermann; J Plaschkes
Journal:  Pediatr Surg Int       Date:  2003-09-11       Impact factor: 1.827

Review 10.  Late Effects in Survivors of Neonatal Cancer.

Authors:  Sanyukta K Janardan; Karen E Effinger
Journal:  Clin Perinatol       Date:  2021-01-12       Impact factor: 3.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.